Cancer Family
Malignant Genitourinary System Neoplasm
CI-CAN-00000233Explore in graph →
3,549 active trials61 approved drugs295 evidence items
- NCIt
- C156484
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000233Explore in graph →
Clinical trials
15,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,963)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02514213 | Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer | completed | Phase 1 | 62 | Inovio PharmaceuticalsINDUSTRY | 1 | Dec 26, 2017 | clinicaltrials |
| NCT01145430 | Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Dec 22, 2017 |
| clinicaltrials |
| NCT02118285 | Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | completed | Phase 1 | 2 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT00287911 | Topotecan, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Cervical Cancer | completed | Phase 1 | 18 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT00622674 | Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 37 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT00005023 | Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer | completed | Phase 1 | — | University of WashingtonOTHER | 1 | Nov 30, 2017 | clinicaltrials |
| NCT00287885 | Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer | completed | Phase 1 | 18 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Nov 29, 2017 | clinicaltrials |
| NCT00365287 | Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer | completed | Phase 1 / Phase 2 | 148 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Nov 29, 2017 | clinicaltrials |
| NCT00620295 | Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors | completed | Phase 1 | 17 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT00703638 | Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 16 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT00526617 | A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients | completed | Phase 1 | 41 | AbbVieINDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT01085422 | A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer | completed | Phase 1 | 35 | AbbVie (prior sponsor, Abbott)INDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT01264432 | Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 2 | Nov 21, 2017 | clinicaltrials |
| NCT01853306 | A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors | completed | Phase 1 | 71 | AbbVieINDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT02009631 | A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors | completed | Phase 1 | 45 | AbbVieINDUSTRY | 3 | Nov 20, 2017 | clinicaltrials |
| NCT02483104 | Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer | completed | Phase 1 | 9 | AbbVieINDUSTRY | 1 | Nov 20, 2017 | clinicaltrials |
| NCT02705469 | A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 | 44 | Zenith EpigeneticsINDUSTRY | 1 | Nov 20, 2017 | clinicaltrials |
| NCT00158782 | Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients | completed | Phase 1 | 75 | GlaxoSmithKlineINDUSTRY | 2 | Nov 17, 2017 | clinicaltrials |
| NCT00363194 | A Two-way Crossover Study Of The Effect Of Food On The Pharmacokinetics Of Pazopanib In Cancer Patients | completed | Phase 1 | 28 | GlaxoSmithKlineINDUSTRY | 1 | Nov 17, 2017 | clinicaltrials |
| NCT00478725 | Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034 | completed | Phase 1 | 10 | GlaxoSmithKlineINDUSTRY | 1 | Nov 17, 2017 | clinicaltrials |
| NCT00861029 | VEG111485: A QTc Study of Pazopanib | completed | Phase 1 | 2 | GlaxoSmithKlineINDUSTRY | 1 | Nov 14, 2017 | clinicaltrials |
| NCT00401583 | A Study To Test The Effect Of GW786034 (Pazopanib) On P450 Enzymes | completed | Phase 1 | 24 | GlaxoSmithKlineINDUSTRY | 2 | Nov 13, 2017 | clinicaltrials |
| NCT00516672 | Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors | completed | Phase 1 | 30 | GlaxoSmithKlineINDUSTRY | 1 | Nov 13, 2017 | clinicaltrials |
| NCT00992121 | An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell Carcinoma | completed | Phase 1 | 11 | GlaxoSmithKlineINDUSTRY | 1 | Nov 13, 2017 | clinicaltrials |
| NCT02916537 | A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057 | completed | Phase 1 | 20 | Cancer Targeted TechnologyINDUSTRY | 1 | Nov 6, 2017 | clinicaltrials |
| NCT00331344 | Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy | completed | Phase 1 / Phase 2 | 100 | National Cancer Institute (NCI)NIH | 1 | Oct 31, 2017 | clinicaltrials |
| NCT02468284 | Pharmacokinetics of Degarelix in Chinese Patients With Prostate Cancer | completed | Phase 1 | 15 | Ferring PharmaceuticalsINDUSTRY | 1 | Oct 26, 2017 | clinicaltrials |
| NCT01938573 | Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer | completed | Phase 1 / Phase 2 | 21 | University of WashingtonOTHER | 1 | Oct 20, 2017 | clinicaltrials |
| NCT01281488 | Fluorescence Imaging in Finding Tumors in Patients With Kidney Tumors | completed | Phase 1 | 28 | City of Hope Medical CenterOTHER | 1 | Oct 13, 2017 | clinicaltrials |
| NCT00499135 | Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors | completed | Phase 1 | 25 | National Cancer Institute (NCI)NIH | 1 | Oct 10, 2017 | clinicaltrials |
| NCT02911350 | Safety Study of Combination of Hormone Therapy, Paclitaxel and Radiation Therapy to Treat Prostate Cancer | completed | Phase 1 | 23 | NYU Langone HealthOTHER | 0 | Oct 2, 2017 | clinicaltrials |
| NCT01254578 | Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers | completed | Phase 1 | 17 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2017 | clinicaltrials |
| NCT02654938 | Safety and Tolerability Clinical Trial of Different Doses of the Immunotherapeutic Drug Mobilan (M-VM3) and Placebo in Patients With Prostate Cancer | completed | Phase 1 | 32 | Panacela Labs LLCINDUSTRY | 1 | Sep 20, 2017 | clinicaltrials |
| NCT01727076 | Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer | completed | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Sep 15, 2017 | clinicaltrials |
| NCT02280811 | T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers | completed | Phase 1 / Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Sep 6, 2017 | clinicaltrials |
| NCT01256268 | Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids | completed | Phase 1 | 24 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 30, 2017 | clinicaltrials |
| NCT00575952 | Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer | completed | Phase 1 | 27 | Gynecologic Oncology GroupNETWORK | 1 | Aug 24, 2017 | clinicaltrials |
| NCT01832870 | Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer | completed | Phase 1 | 9 | Prostate Oncology Specialists, Inc.OTHER | 1 | Aug 24, 2017 | clinicaltrials |
| NCT02852564 | Ethacrynic Acid Elimination in Non-Muscle Invasive Bladder Cancer Patients Undergoing Transurethral Resection | completed | Phase 1 | 12 | Eugene Lee, MDOTHER | 1 | Aug 22, 2017 | clinicaltrials |
| NCT02015416 | A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer | completed | Phase 1 | 13 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Aug 17, 2017 | clinicaltrials |
| NCT02482090 | TIL Therapy for Metastatic Ovarian Cancer | completed | Phase 1 | 6 | Inge Marie SvaneOTHER | 1 | Aug 16, 2017 | clinicaltrials |
| NCT00531284 | Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma | completed | Phase 1 / Phase 2 | 184 | AmgenINDUSTRY | 1 | Aug 15, 2017 | clinicaltrials |
| NCT00958477 | A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate Cancer | completed | Phase 1 | 26 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 2 | Aug 2, 2017 | clinicaltrials |
| NCT01594918 | Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 | 25 | Rahul AggarwalOTHER | 1 | Jul 21, 2017 | clinicaltrials |
| NCT00924313 | Positron Emission Tomography and Magnetic Resonance Imaging for Prostate Cancer | completed | Phase 1 / Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jul 11, 2017 | clinicaltrials |
| NCT01240629 | Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 43 | University of Southern CaliforniaOTHER | 1 | Jul 11, 2017 | clinicaltrials |
| NCT03074032 | Safety, Tolerability and Pharmacokinetics of ONC1-0013B in Patients With Progressive Metastatic Castration-resistant Prostate Cancer | completed | Phase 1 | 17 | Avionco LLCINDUSTRY | 1 | Jul 11, 2017 | clinicaltrials |
| NCT02225093 | A Study to Evaluate How Daily Dosing With Enzalutamide Affects the Metabolism of Caffeine and Dextromethorphan in Men With Prostate Cancer | completed | Phase 1 | 12 | Astellas Pharma Europe B.V.INDUSTRY | 1 | Jun 27, 2017 | clinicaltrials |
| NCT01911728 | Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates | completed | Phase 1 | 14 | Astellas Pharma Europe B.V.INDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT02237690 | Assess Bioequivalence of Two Formulations of Doxorubicin Hydrochloride Liposome in Female Patients With Ovarian Cancer | completed | Phase 1 | 30 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 5, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Dec 26, 2017source: clinicaltrials